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Abstract
Eight N-acetylglucosamine-1-phosphate and N-acetylgalactosamine-1-phosphate analogs have
been synthesized chemically and were tested for their recognition by the GlmU uridyltransferase
enzyme. Among these, only substrates that have an amide linkage to the C-2 nitrogen were
transferred by GlmU to afford their corresponding uridine diphosphate(UDP)-sugar nucleotides.
Resin-immobilized GlmU showed comparable activity to non-immobilized GlmU and provides a
more facile final step in the synthesis of an unnatural UDP-donor. The synthesized unnatural
UDP-donors were tested for their activity as substrates for glycosyltransferases in the preparation
of unnatural glycosaminoglycans in vitro. A subset of these analogs was useful as donors,
increasing the synthetic repertoire for these medically important polysaccharides.
1. Introduction
Glycosaminoglycans (GAGs) are a family of polysaccharides that are prevalent both as free
glycans and in the core structures of glycans in glycoproteins1 and glycolipids,2 affecting
cell–cell interactions during various metabolic processes.3 They are composed of repeating
disaccharide units containing hexosamine residues; the other part of the repeat is often an
uronic acid residue. N-Acetylglucosamine (GlcNAc) is found in heparosan, heparin, heparan
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Monosaccharides in the form of UDP-nucleotides act as donors being transferred to a
glycosyl acceptor by a glycosyltransferase or a synthase in the polysaccharide biosynthetic
pathway.4 Natural and unnatural GAGs can be prepared in the laboratory5 by using
recombinant GAG synthases and chemically prepared UDP-sugar nucleotides. With the
advent of recombinant technology, glycosyltransferases and synthases have now become
readily available. A major limitation to the enzymatic preparation of GAG polysaccharides
and oligosaccharides is the limited availability and cost of sugar nucleotides and of sugar
nucleotide analogs and derivatives due to the difficulty of their syntheses.6 Though they can
be prepared in several ways, a purely chemical approach requires a long and tedious
synthesis and yields of UDP-donor are generally low. Enzymatic synthesis offers an
alternative to the use of protection and deprotection steps required for chemical synthesis7
and circumvents the difficulties inherent to the formation of a pyrophosphate bond.
Wang et al. reported the enzymatic synthesis of UDP-GlcNAc/UDP-GalNAc analogs using
recombinant Escherichia coli N-acetylglucosamine-1-phosphate uridyltransferase (GlmU).8
However they reported low yields, especially for N-modified GalNAc-1-phosphate analogs
and later turned to recombinant human UDP-GalNAc pyrophosphorylase (AGX1) for the
synthesis of UDP-GalNAc analogs.9 More recently, Chen et al. reported a one-pot three-
enzyme synthesis of UDP-GlcNAc derivatives using an N-acetylhexosamine 1-kinase and
GlmU but only a few derivatives were successfully synthesized.10 Here we report the
chemical synthesis of eight different GlcNAc-1-phosphate and GalNAc-1-phosphate analogs
and their recognition by the GlmU enzyme (Figure 1).
2. Results and Discussion
2.1 Synthesis of N-acetylglucosamine-1-phosphate and N-acetylgalactosamine-1-
phosphate analogs
Eight natural and unnatural N-acetylglucosamine-1-phosphates and N-
acetylgalactosamine-1-phosphates were chemically synthesized from commercially
available monosaccharides. Our first attempt aimed at synthesizing GlcNH2-1-phosphate,
since the amine group can be easily functionalized at a later step. As shown in Scheme 1,
reactions of glucosamine hydrochloride (1) with in situ generated TfN3 afforded 2-azido
sugar 2 in 89% yield, which was subsequently peracetylated.11 MacDonald
phosphorylation12 of the protected 2-azido sugar gave monophosphate 4 in a modest 46%
yield. Subjecting 4 to Zemplén conditions removed its acetyl groups, affording GlcN3-1-
phosphate (5). Finally, reduction of 5 by hydrogenation using the Lindlar’s catalyst13
afforded GlcNH2-1-phosphate (6) in quantitative yield.
Next, GlcNAc-1-phosphate (7), the natural substrate of GlmU, was chemically synthesized
from 6 through N-acetylation using Ac2O in MeOH/H2O (1/3) followed by treatment with
MeOH/H2O/Et3N (2/2/1) to remove any O-acetyl groups that had been introduced (Scheme
2). Next, GalNAc-1-phosphate (9), an unnatural substrate of GlmU, was synthesized to
investigate the impact of the C4 configuration on GlmU recognition. Compound 9, a C4
epimer of 7, was prepared from the commercially available galactosamine (8).
Unnatural UDP-GlcNAc and UDP-GalNAc analogs having a ‘clickable’14 alkyne group
were also synthesized. In our initial approach, we attempted to functionalize glucosamine
hydrochloride in the first step with propiolic acid under several different coupling
conditions, but this led to low yields and separation difficulties. Instead, the stepwise
synthesis of GlcN-alkyne-1-phosphate was undertaken as shown in Scheme 3. 2-Azido-D-
glucose tetraacetate (3) was reduced by hydrogenation with Lindlar’s catalyst to afford 10.
The amino sugar 10 was then acylated using propiolic anhydride, prepared by treating
propiolic acid with DCC in DCM, and affording the alkyne derivative in 70% yield.
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MacDonald phosphorylation12 followed by de-O-acetylation provided GlcN-alkyne-1-
phosphate (13). GalN-alkyne-1-phosphate (18) was similarly synthesized using CBz
protection of the amino group (Scheme 4):
Next, a bioisostere of GlcNAc-1-phosphate bearing an N-trifluoroacetamide was synthesized
(Scheme 5). The N-trifluoroacetyl (TFA) group represents an excellent protecting group in
the chemoenzymatic synthesis of GAGs,15 as it can undergo selective deprotection by mild
base treatment and then can be readily N-sulfonated to afford heparin and heparan sulfate
type glycans. First, D-glucosamine hydrochloride (1) was protected as an N-trifluoroacetyl by
treatment of CF3CO2Et16 followed by peracetylation. Phosphorylation12 followed by
Zemplén deprotection afforded GlcN-TFA-1-phosphate (22).
A ‘thiol-clickable’17 analog, with an N-ene, was next synthesized from commercially
available tetra-O-acetyl glucosamine (23). The per-O-acetylated sugar was chosen as the
starting material, as the unprotected monosaccharide was prone to polymerization upon
treatment with acryloyl chloride. Thus, treatment of the tetraacetate with acryloyl chloride
introduced an ene group to afford compound 24. Phosphorylation proceeding in low yield
was followed by deacetylation to give monophosphate 26.
2.2 Preparation of the UDP-Sugar Nucleotides
After the successful synthesis of a small library of GlcNAc-1-phosphate and GalNAc-1-
phosphate analogs, each substrate was tested for its recognition by GlmU from Escherichia
coli.15 The enzymatic reaction was performed in Tris buffer with MgCl2, DTT, UTP, and
inorganic pyrophosphatase at 30 °C for 3 h (2 days for UDP-GalNAc analogs).18 The results
are shown in Table 1.
Out of the eight analogs tested, six were accepted as substrates by GlmU, affording the
corresponding UDP-sugar nucleotides in high yields. Neither GlcN3-1-phosphate (5) nor
GlcNH2-1-phosphate (6) was accepted by GlmU. GlcNAc-1-phosphate (7) and GlcN-
TFA-1-phosphate (22) were excellent substrates, yielding more than 70% conversion. Since
GalNAc-1-phosphate (9) was accepted by GlmU, the 4-OH group appears not to play a
critical role in enzyme recognition. Both GlcN-alkyne-1-phosphate (13) and GalN-alkyne-1-
phosphate (18) gave moderate yields of UDP-sugars using GlmU. Based on these
observations, it appears that the amide bond on the 2-amino functional group is essential for
substrate recognition by GlmU but the configuration at C4 is not important.
Immobilization of (His)6-tagged enzymes on Ni beads has been useful in carbohydrate
synthesis.19, 20 Since the reactions above using the soluble enzyme showed promising
yields, we examined the immobilization of GlmU for future applications in large-scale
synthesis. Taking advantage of the C-terminal (His)6-tag, GlmU was immobilized on Ni
Sepharose beads that were then added to the reaction mixture using 22 as the substrate.
Immobilized GlmU gave high yields of UDP-GlcN-TFA, comparable to that of the solution-
based reaction. The same beads could be recycled and reused for a second reaction, and
retained high enzymatic activity. Recycling the enzyme through its immobilization avoids
the requirement of repeated enzyme expression, and can allow for continuous processes and
eases the purification of UDP-sugar nucleotide product.
Although UDP-GlcN3 and UDP-GlcNH2 could not be synthesized using GlmU, they were
chemically synthesized from the aforementioned GlcN3-1-phosphate (5) (Scheme 7).
Compound 5 was converted to its pyridinium salt, then stirred with UMP-morpholidate21 in
pyridine for 5 days to afford UDP-GlcN3 (33). The azide group was then reduced to an
amine by hydrogenation using Lindlar’s catalyst, affording UDP-GlcNH2 (34). This free
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amino group was then functionalized to afford the following unnatural UDP-GlcNAc
analogs: UDP-GlcN-biotin (35), UDP-GlcN-Fmoc (36), and UDP-GlcN-tBoc (37).
These ten UDP-sugar nucleotides were then tested for incorporation by various GAG
synthases in vitro. PmHAS and PmCS produce hyaluronan and chondroitin polysaccharides,
respectively.22 PmHS1 and PmHS2 are two homologous isozymes that both can polymerize
heparosan, the precursor of heparan sulfate and heparin.5 The hexosamine analogs were
tested in a chain polymerization assay using radioactively labeled UDP-[3H]GlcUA; a
radioactive signal results only if the hexosamine is co-polymerized into the disaccharide
repeats of a GAG product.5, 23
The results shown in Table 2 demonstrate that some analogs function well with one or more
synthases, but a few analogs did not incorporate into polymer under our conditions. In
addition to increasing the chemical functionality of synthetic GAGs, the substrate specificity
information yields insights into the synthases’ recognition of their donor precursors.
Conclusions
In conclusion, we synthesized a small library of GlcNAc/GalNAc-1-phosphate analogs for
their recognition by the GlmU uridyltransferase to synthesize UDP-GlcNAc/GalNAc
analogs. Only analogs with an amide linkage at the C-2 nitrogen were successfully accepted
by GlmU and gave the product in moderate to high yields. Analogs without an amide
linkage were converted to UDP-sugar donors by chemical synthesis. The UDP-sugars were
then tested for incorporation by GAG synthases using a radioactive assay, which showed
that natural and unnatural UDP-sugars were incorporated into the polysaccharide. These
results demonstrate that unnatural GAGs with a desired functionality can be synthesized in
vitro and has promising therapeutic applications.
Experimental Section
General
1H and 13C NMR spectra were recorded at 500 MHz for 1H NMR, 125 MHz for 13C NMR,
or 600 MHz for 1H NMR, 150 MHz for 13C NMR, or 800 MHz (800 MHz for 1H NMR,
200 MHz for 13C NMR) with Topsin 2.1 software. Mass data were acquired by high-
resolution ESI-MS. Thin-layer chromatography (TLC) was carried out using plates of silica
gel 60 with fluorescent indicator and revealed with UV light (254 nm) when possible and
Von’s reagent or ninhydrin solution in ethanol. Flash chromatography was performed using
silica gel 230–400 mesh. Yields are given after purification, unless otherwise noted. When
reactions were performed under anhydrous conditions, the mixtures were maintained under
argon. Compounds were named following IUPAC rules as applied by Beilstein-Institute
AutoNom (version 2.1) software for systematic names in organic chemistry.
Expression of GlmU enzyme
The procedures for the expression and purification of GlmU were described previously.24
Briefly, GlmU was cloned into a PET 21b vector (Novagen) to form a C-terminal (His)6-
tagged fusion protein. The expression was carried out in BL21 star cells (Invitrogen). The
protein was purified by a Ni-Sepharose 6 Fast Flow column (GE Health) following a
standard procedure.
General procedure for the MacDonald phosphorylation
Crystalline phosphoric acid (8.1 mmol) was dried in vacuo over phosphorous pentoxide for
12 h. The 1-O-acetyl sugar derivative (1 mmol) was added and the mixture was heated at 60
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°C in vacuo. After 2 h, heating was ceased and the resulting dark black mixture was
dissolved in anhydrous THF (5 mL). The solution was cooled to 0 °C and concentrated
ammonium hydroxide (0.5 mL) was added until ~pH 7. The precipitate of ammonium
phosphate was filtered off and washed with THF (20 mL). The combined filtrate and
washings were evaporated to give a syrupy residue that was purified by flash column
chromatography (EtOAc 100% to EtOAc/MeOH 50/50).
General procedure for Zemplén deacetylation
Sodium methoxide (3 mmol) in MeOH (0.5 M) was added to the peracetylated phosphate (1
mmol) in MeOH (7 mL) at 0 °C. The reaction was stirred at 0 °C for 1 h and quenched with
Amberlite IR-120 (H+). Amberlite was removed through filtration and the filtrate was
concentrated in vacuo to afford the fully deprotected phosphate in quantitative yield.
General procedure for the enzymatic preparation of the UDP-sugar nucleotides
A reaction mixture containing the monophosphate, glucosamine-1-phosphate
acetyltransferase/N-acetyl glucosamine-1-phosphate uridyltransgerase (GlmU), Tris-HCl
(46 mM, pH 7.0), MgCl2 (5 mM), dithiothreitol (200 µM), UTP (2.5 mM), inorganic
pyrophosphatase (0.012 units/µL), from Sigma-Aldrich, was incubated at 30 °C for 3 h. For
GalNAc substrates, a second portion of GlmU was added to the reaction mixture on the
second day. The completion of the reaction was monitored by by TLC (n-butanol/formic
acid/methanol=4/8/1) or through MS. Then 3 reaction volumes of ethanol was added to
quench the reaction and stored overnight at −20 °C. Centrifugation at 3000 rcf for 30 min
afforded the crude product in the supernatant which was then concentrated and further
purified on a BioGel (Bio-Rad) P2 column (2.5 × 65cm) and eluted with H2O. Fractions
were collected and those containing the product as determined by UV absorbance at 262 nm
were combined and freeze-dried to afford the pure product.
2-azido-2-deoxy-D-glucopyranose-3,4,6-triacetate-1-dihydrogen phosphate (4)
—Brown oil; 1H NMR (500 MHz, MeOD): δ (ppm) 5.73 (s, 1H), 5.49 (t, J = 9.5 Hz, 1H),
5.12 (t, J = 9.74 Hz, 1H), 4.36 (d, J = 10 Hz, 2H), 4.14 (m, 1H), 3.65 (d, J = 9 Hz, 1H), 2.08
(s, 3H), 2.04 (s, 6H); 13C NMR (125 MHz, MeOD): δ (ppm) 171.1, 170.2, 170.0, 93.4, 70.7,
68.4, 68.0, 61.4, 61.2, 61.1; HRMS-FAB: [M−H] calcd. for C12H17N3O11P− 410.0606
Found: 410.0601.
2-azido-2-deoxy-D-glucopyranose-1-dihydrogen phosphate (5)—Light brown
amorphous solid; 1H NMR (500 MHz, D2O): δ (ppm) 5.54 (dd, 1H, J = 7.4 Hz, 3.1 Hz),
3.88-3.72 (m, 4H), 3.48 (t, 1H, J = 9.5 Hz), 3.29 (d, 1H, J = 2.5 Hz); 13C NMR (125 MHz,
D2O): δ (ppm) 94.0, 72.8, 70.7, 69.5, 62.8, 60.3; HRMS-FAB: [M−H] calcd. for
C6H11N3O8P− 284.0289 Found: 284.0289.
2-amino-2-deoxy-D-glucopyranose-1-dihydrogen phosphate (6)—Lindlar’s
catalyst (20 mg) was added to a stirred solution of 5 (75 mg, 0.228 mmol) in MeOH/H2O,
1/1 (10 mL). A hydrogen balloon was attached to the reaction flask and the reaction was
stirred overnight at room temperature. The reaction mixture was filtered through Celite and
rinsed with water. The filtrate and washings were combined and concentrated to afford 6 in
quantitative yield.
1H NMR (800 MHz, D2O): δ (ppm) 5.59 (1H, dd, J = 7.4 Hz, 3.1 Hz), 3.90-3.84 (3H, m),
3.73 (1H, m), 3.45 (1H, m), 3.26 (1H, m); 13C NMR (200 MHz, D2O): δ (ppm) 90.8, 72.1,
69.6, 69.4, 60.1, 54.4; HRMS-FAB: [M−H] calcd. for C6H13NO8P− 258.0384 Found:
258.0391.
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(11)—To a stirred solution of DCC (740 mg, 3.59 mmol) in dry CH2Cl2 (19.5 mL),
propiolic acid (0.18 mL, 2.92 mmol) was slowly added at 0 °C. After 1h, 10 (1.267 g, 2.924
mmol), dissolved in dry CH2Cl2 (7 mL), and DIPEA was added dropwise. The reaction
mixture was stirred for 1 h at 0 °C, then warmed to room temperature and then stirred for
another 2 h before the solvents were removed in vacuo. The crude product was purified by
silica gel chromatography (MeOH/CH2Cl2, 1/20) to yield 11 as a colorless amorphous solid
(1.20 g, 70%). 1H NMR (500 MHz, CDCl3): δ (ppm) 6.01 (d, 1 H, J = 9.4 Hz), 5.69 (d, 1 H,
J = 8.7 Hz), 5.14 (m, 2 H), 4.34 (m, 1 H), 4.27 (dd, 1 H, J = 4.2, 12.5 Hz), 4.12 (d, 1 H, J =
12.5 Hz), 3.81 (m, 1 H), 2.13-2.04 (4s, 12 H); 13C NMR (125 MHz, CDCl3): δ (ppm) 171.2,
170.7, 169.5, 169.4, 152.1, 92.0, 76.5, 74.7, 72.5, 72.2, 68.0, 61.6, 52.6, 20.8-20.5; HRMS-
FAB: [M+Na] calcd. for C17H21NNaO10+ 422.1063 Found: 422.1065.
2-deoxy-2-[(1-oxo-2-propyn-1-yl)amino]-D-glucopyranose-3,4,6-triacetate-1-
dihydrogen phosphate (12)—Brown oil; 1H NMR (500 MHz, CDCl3): δ (ppm) 6.01 (d,
J = 9.4 Hz, 1 H), 5.69 (d, J = 8.7 Hz, 1 H), 5.14 (m, 2 H), 4.34 (m, 1 H), 4.27 (dd, J = 4.2,
12.5 Hz, 1 H), 4.12 (d, J = 12.5 Hz, 1 H), 3.81 (m, 1 H), 2.13-2.04 (4s, 12 H); 13C NMR
(125 MHz, CDCl3): δ (ppm) 171.2, 170.7, 169.5, 169.4, 152.1, 92.0, 76.5, 74.7, 72.5, 72.2,
68.0, 61.6, 52.6, 20.8-20.5; HRMS-FAB: [M+Na] calcd. for C17H21NNaO10+ 422.1063
Found: 422.1065.
2-deoxy-2-[(1-oxo-2-propyn-1-yl)amino]-D-glucopyranose-1-dihydrogen
phosphate (13)—Light brown amorphous solid; 1H NMR (500 MHz, D2O): δ (ppm) 5.32
(dd, J = 3.3, 7.0 Hz,1 H), 3.87 (dt, J = 2.6, 10.5 Hz, 1 H), 3.72 (dd, J = 2.4, 4.2 Hz, 1 H),
3.70-3.64 (m, 3 H) 3.38 (dd, J = 9.1, 10.0 Hz, 1 H), 3.35 (s, 1 H); 13C NMR (125 MHz,
D2O): δ (ppm) 152.5, 95.5, 77.8, 75.0, 73.2, 63.9, 62.9, 56.7, 56.6; HRMS-FAB: [M−H]
calcd. for C9H13NO9P− 310.0328 Found: 310.0323.
2-deoxy-2-[[(phenylmethoxy)carbonyl]amino]-D-galactopyranose-1,3,4,6-
tetraacetate (15)—Galactosamine·HCl (5.0 g, 23 mmol) was dissolved in 130 mL of 0.5
M NaOMe in MeOH and stirred for 35 min. The reaction mixture was cooled to 0 °C, 3.23
mL (23.2 mmol) of Et3N and 5.0 g (23 mmol) of benzyl chloroformate were added, and the
mixture was stirred for 5 h. The thick suspension was concentrated and dissolved in 25 mL
of Ac2O and 50 mL of pyridine. A catalytic amount of N,N-(dimethylamino)pyridine
(DMAP) was added, and the solution was stirred overnight. It was concentrated and
coevaporated with toluene (6 × 25 mL). The resulting syrup was dissolved in 40 mL of
CHCl3 and washed with saturated CuSO4 (2 × 20 mL), saturated NaHCO3 (2 × 25 mL), and
brine (1 × 25 mL). The combined aqueous layers were extracted with 40 mL of CHCl3, and
the combined organic layers were dried over Na2SO4. The crude product was concentrated
and purified by silica gel chromatography eluting with a gradient of 200/1 to 20/1, CHCl3/
MeOH, to yield 6.3 g (52%) of a yellow syrup comprising a mixture of anomers. 1H NMR
(500 MHz, CDCl3): δ 7.32 (m, 5 H), 6.22 (dd, 1 H, J = 3.65 Hz), 5.39 (m, 1 H), 5.12-4.99
(m, 3 H), 4.43 (m, 1 H), 4.12-3.98 (m, 3 H), 2.12 (s, 3 H), 2.09 (s, 3 H), 1.98 (s, 3 H), 1.89
(s, 3 H); 13C NMR (125 MHz, CDCl3): δ 170.4, 170.3, 170.3, 168.8, 155.4, 136.7, 128.5,
91.4, 77.3, 68.4, 68.0, 67.1, 66.7, 61.2, 48.6, 20.8, 20.5, 20.4. HRMS-FAB: [M+Na] calcd.
for C22H25NNaO10+ 486.1376 Found: 486.1379.
2-amino-2-deoxy-D-galactopyranose-1,3,4,6-tetraacetate hydrochloride (16)
—1H NMR (500 MHz, CD3OD): δ 6.37 (d, 1 H, J = 3.6 Hz), 5.50 (dd, 1 H, J = 1.3, 3.2 Hz),
5.36 (dd, 1 H, J = 3.2, 8.3 Hz), 4.43 (m, 1 H), 4.12 (d, 1 H, J = 6.6 Hz), 4.09 (d, 1 H, J = 6.6
Hz), 3.96 (dd, 1 H, J = 3.6, 11.4 Hz), 2.21 (s, 3 H), 2.14 (s, 3 H), 2.06 (s, 3 H), 1.89 (s, 3 H);
Masuko et al. Page 6













δ 169.8, 169.4, 168.8, 168.5, 91.6, 67.6, 65.6, 61.2, 55.4, 42.4, 19.1, 17.3, 15.8, 11.2.
HRMS-FAB: [M+Na] calcd. for C14H21NNaO9+ 370.1114 Found: 370.1117.
2-deoxy-2-[(1-oxo-2-propyn-1-yl)amino]-D-galactopyranose-1,3,4,6-tetraacetate
(17)—Colorless oil; 1H NMR (500 MHz, CDCl3): δ 6.10 (d, 1 H, J = 3.6 Hz), 5.32 (m, 1
H), 5.09 (dd, 1 H, J = 3.2, 11.6 Hz), 4.56 (dd, 1 H, J = 3.2, 11.6 Hz), 4.16 (t, 1 H, J = 6.6
Hz), 3.97 (m, 2 H), 3.57 (m, 1 H), 2.93 (s, 1 H), 2.05 (s, 3 H), 2.04 (s, 3 H), 1.90 (s, 3 H),
1.89 (s, 3 H); 13C NMR (125 MHz, CDCl3): δ 170.5, 170.2, 169.4, 168.8, 152.3, 92.5, 77.2,
74.4, 71.5, 70.1, 66.2, 61.3, 49.4, 24.8-22.0; HRMS-FAB: [M+Na] calcd. for
C17H21NNaO10+ 422.1063 Found: 422.1068.
2-deoxy-2-[(1-oxo-2-propyn-1-yl)amino]-α-D-galactopyranose-1-(dihydrogen
phosphate) (18)—Light brown amorphous solid; 1H NMR (500 MHz, CD3OD): δ 5.32
(dd, 1 H, J = 3.4, 7.2 Hz), 4.17 (dt, 1 H, J = 2.6, 10.8 Hz), 4.00 (dd, 1 H, J = 5.7, 6.3 Hz),
3.86 (m, 1 H), 3.80 (dd, 1 H, J = 3.1, 10.0 Hz), 3.59 (m, 1 H), 3.34 (s, 1 H); 13C NMR (125
MHz, CD3OD): δ (ppm) 152.6, 91.4, 68.0, 67.9, 67.5, 67.2, 66.0, 61.9, 61.3; HRMS-FAB:
[M−H] calcd. for C9H13NO9P− 310.0328 Found: 310.0321.
2-deoxy-2-[(trifluoroacetyl)amino]-D-glucopyranose (19)—Et3N (3.50 mL, 25
mmol) and CF3CO2Et (3.8 mL, 32 mmol) were added to D-glucosamine hydrochloride
(5.375 g, 25 mmol) in MeOH (15 mL). The reaction mixture was stirred at room
temperature overnight. The solution was concentrated in vacuo and recrystallized in MeOH
to afford N-trifluoroacetylated 19 (α/β = 1:0.8) (5.26 g, 19.2 mmol, 71%). 1H NMR (500
MHz, D2O): δ (ppm) 8.28 (d, J = 0.76 Hz, 1H), 5.11 (d, J = 3.49 Hz, 1H), 4.63 (d, J = 12.5
Hz, 1H), 3.84 (dd, J = 10.73, 3.53 Hz, 1H), 3.77 (d, J = 1.44 Hz, 1H), 3.75-3.73 (m, 1H),
3.73-3.71 (m, 1H), 3.71-3.69 (m, 1H), 3.68 (d, J = 2.31 Hz, 1H), 3.64 (d, J = 5.20 Hz, 1H),
3.63 (d, J = 2.43 Hz, 1H), 3.62-3.60 (m, 1H), 3.59 (dd, J = 4.87, 2.14 Hz, 1H), 3.49-3.45 (m,
1H), 3.34 (ddd, J = 10.06, 2H); 13C NMR (125 MHz, D2O): δ (ppm) 94.8, 90.5, 76.7, 73.8,
71.7, 70.9, 70.7, 70.4, 61.4, 61.2, 57.7, 55.1; HRMS-FAB: [M−H] calcd. for C8H11F3NO6−
274.0544 Found: 274.0541.
2-deoxy-2-[(trifluoroacetyl)amino]-D-glucopyranose-1,3,4,6-tetraacetate (20)—
Pyridine (56.3 mL) and Ac2O (32.5 mL) were added to 19 (5.26 g, 19.2 mmol). The reaction
mixture was stirred for 3 hours at room temperature. The solution was concentrated in vacuo
and co-evaporated with toluene (10 mL) three times. The resulting residue was recrystallized
in Et2O (15 mL) and petroleum ether (5 mL) to afford peracetylated 20 (α:β = 1:0.33, 8.51 g,
19.2 mmol, quant.). 1H NMR (500 MHz, CDCl3): δ (ppm) 6.60 (d, J = 9.28 Hz, 1H), 6.51
(d, J = 8.50 Hz, 1H), 6.27 (d, J = 3.66 Hz, 1H), 5.76 (d, J = 8.71 Hz, 1H), 5.35-5.28 (m, 1H),
5.25 (t, J = 9.74, 1H), 5.22-5.16 (m, 1H), 4.45 (ddd, J = 10.84, 8.69, 3.66 Hz, 1H), 4.33-4.27
(m, 2H), 4.15 (dd, J = 12.56, 2.28 Hz, 1H), 4.09 (dd, J = 12.50, 2.33 Hz, 1H), 4.04 (ddd, J =
9.95, 3.97, 2.32 Hz, 1H), 3.85 (ddd, J = 9.50, 4.50, 2.18 Hz, 1H), 2.23 (s, 3H), 2.13 (s, 6H),
2.11 (s, 6H), 2.08 (s, 3H), 2.08 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H); 13C NMR (500 MHz,
CDCl3): δ (ppm) 171.7, 170.7, 169.2, 168.6, 157.5, 157.2, 116.5, 114.2, 91.7, 89.6, 72.8,
71.9, 70.1, 69.7, 67.9, 67.2, 61.6, 61.3, 53.1, 51.7; HRMS-FAB: [M−H] calcd. for
C16H19F3NO10− 442.0967 Found: 442.0961.
2-deoxy-2-[(trifluoroacetyl)amino]-D-glucopyranose-3,4,6-triacetate-1-
dihydrogen phosphate (21)—1H NMR (500 MHz, D2O): δ (ppm) 5.70-5.55 (m, 1H),
5.43 (s, 1H), 5.14 (s, 1H), 4.36 (s, 2H), 4.24-4.09 (m, 1H), 3.34 (d, J = 19.11 Hz, 1H), 2.08
(s, 3H), 2.01 (s, 3H), 1.94 (s, 3H); 13C NMR (125 MHz, D2O): δ (ppm) 171.3, 170.4, 169.8,
157.2, 114.7, 92.7, 71.2, 68.2, 68.1, 61.4, 52.8; HRMS-FAB: [M−H] calcd. for
C14H18F3NO12P− 480.0524 Found: 480.0524.
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(22)—1H NMR (500 MHz, D2O): δ (ppm) 5.44 (dd, J = 7.32, 3.23 Hz, 1H), 4.03 (ddd, J =
10.57, 3.17, 1.84 Hz, 1H), 3.94 (ddd, J = 10.12, 4.89, 2.22 Hz, 1H), 3.77 (dd, J = 12.38, 4.94
Hz, 1H), 3.87 (ddd, J = 12.31, 9.99, 5.66 Hz, 1H), 3.51 (dd, J = 10.06, 9.14 Hz, 1H); 13C
NMR (125 MHz, D2O): δ (ppm) 159.4, 116.7, 92.6, 72.6, 69.9, 69.5, 60.2, 54.3; HRMS-
FAB: [M−H] calcd. for C8H12F3NO9P− 354.0207 Found: 354.0206.
2-deoxy-2-[(1-oxo-2-ethen-1-yl)amino]-α-D-glucopyranose-1,3,4,6-tetraacetate
(24)—Et3N (145 µL, 1.04 mmol) was added to a stirred solution of 1,3,4,6-O-acetyl-2-
amino-2-deoxy-β-D-glucopyranose·HCl (200 mg, 0.521 mmol). The solution was cooled to
0 °C and acryloyl chloride (50 µL, 0.625 mmol) was added dropwise. The reaction mixture
was stirred overnight at room temperature. The solution was concentrated in vacuo and
purified on silica gel chromatography (hexanes 100% to hexanes/EtOAc = 1/1) to afford 24
as a clear syrup (170 mg, 81%).
1H NMR (500 MHz, CDCl3): δ (ppm) 6.96 (d, J = 9.59 Hz, 1H), 6.20 (d, J = 17.1 Hz, 1H),
6.00 (dd, J = 17.1, 10.4 Hz, 1H), 5.68 (d, J = 8.8 Hz, 1H), 5.61 (d, J = 9 Hz, 1H), 5.17 (t, J =
11 Hz, 1H), 5.07 (t, J = 9.65 Hz, 1H), 4. 34 (dd, J = 19.42, 9.61 Hz, 1H), 4.21 (td, J = 9.10,
4.57 Hz, 1H), 4.08 (dd, J = 12.44, 2.15 Hz, 1H), 3.81 (ddd, J = 9.85, 4.55, 2.19 Hz, 1H),
2.04-1.95 (s, 12H); 13C NMR (125 MHz, CDCl3): δ (ppm) 171.2, 170.9, 169.7, 169.4,
166.0, 130.1, 127.4, 92.4, 72.6, 72.6, 68.0, 61.7, 61.7, 52.5, 50.3; HRMS-FAB: [M+H]
calcd. for C17H24NO10+ 402.1400 Found: 402.1395.
2-deoxy-2-[(1-oxo-2-ethen-1-yl)amino]-α-D-glucopyranose-3,4,6-triacetate-1-
(dihydrogen phosphate) (25)—Brown oil; 1H NMR (500 MHz, MeOD): δ (ppm) 6.28
(d, J = 9.92 Hz, 17 Hz, 1H), 6.22 (dd, J = 17.5, 2.05 Hz,1H), 5.66 (dd, J = 9.93, 2.05 Hz,
1H), 5.52 (dd, J = 6.63, 3.26 Hz, 1H), 5.36 (dd, J = 10.49, 9.59 Hz, 1H), 5.11 (t, J = 9.75,
9.75 Hz, 1H), 4.39-4.34 (m, 1H), 4.31 (dd, J = 9.20, 6.05 Hz, 2H), 4.29-4.26 (m, 1H),
4.17-4.11 (m, 1H), 2.00 (s, 6H), 1.94 (s, 3H); 13C NMR (125 MHz, MeOD): δ (ppm) 171.1,
170.5, 169.9, 166.7, 130.3, 126.1, 93.7, 71.4, 68.3, 68.2, 61.5, 51.9, 50.3 ; HRMS-FAB: [M
−H] calcd. for C15H21NO12P− 438.0807 Found: 438.0800.
2-deoxy-2-[(1-oxo-2-ethen-1-yl)amino]-α-D-glucopyranose-3,4,6-1-(dihydrogen
phosphate) (26)—Light brown amorphous solid; 1H NMR (500 MHz, D2O): δ (ppm)
6.14 (dd, J = 17.14, 10.20 Hz, 1H), 6.04 (dd, J = 17.14, 1.35 Hz, 1H), 5.60 (dd, J = 10.23,
1.34 Hz, 1H), 5.28 (dd, J = 6.63, 3.26 Hz, 1H), 3.88-3.83 (m, 1H), 3.68 (dd, J = 6.66, 3.67
Hz, 1H), 3.65-3.62 (m, 3H), 3.59 (m, 1H); 13C NMR (125 MHz, D2O): δ (ppm) 165.8,
129.4, 128.0, 93.5, 72.6, 70.4, 69.4, 60.1, 53.7; HRMS-FAB: [M−H] calcd. for
C9H15NO9P− 312.0490 Found: 312.0486.
P'-[2-(acetylamino)-2-deoxy-α-D-glucopyranosyl] ester-uridine 5'-(trihydrogen
diphosphate), (UDP-GlcNAc, 27)—1H NMR (500 MHz, D2O): δ (ppm) 7.87 (dd, J =
8.08, 2.41 Hz, 1H), 5.93-5.86 (m, 2H), 5.44 (d, J = 3.28 Hz, 1H), 4.32-4.25 (m, 2H),
4.24-4.08 (m, 3H), 3.94-3.88 (m, 1H), 3.86 (ddd, J = 8.03, 5.20, 2.66 Hz, 1H), 3.80 (dd, J =
17.63, 9.17 Hz, 1H), 3.73 (ddd, J = 18.49, 9.53, 5.39 Hz, 2H), 3.47 (ddd, J = 9.52, 5.51, 3.38
Hz, 1H), 2.02-1.95 (s, 3H); 13C NMR (125 MHz, D2O): δ (ppm) 174.7, 166.7, 152.1, 141.4,
102.6, 94.3, 88.4, 83.0, 73.7, 72.9, 70.8, 69.5, 69.4, 64.9, 60.2, 53.5, 22.0; HRMS-FAB: [M
−H] calcd. for C17H26N3O17P2− 606.0743 Found: 606.0734.
P'-[2-(1-oxo-2-propyn-1-yl)amino-2-deoxy-α-D-glucopyranosyl] ester-uridine 5'-
(trihydrogen diphosphate) (UDP-GlcN-alkyne, 28)—White fluffy powder; 1H NMR
(600 MHz, D2O): δ (ppm) 7.89 (d, J = 8.1 Hz, 1 H), 5.89 (d, J = 4.6 Hz, 1 H), 5.88 (d, J =
8.9 Hz, 1 H), 5.47 (dd, J = 3.2, 6.9 Hz, 1 H), 4.28 (m, 2 H), 4.20 (m, 1 H), 4.18-4.16 (m, 1
Masuko et al. Page 8













H), 4.12-4.09 (m, 1 H), 3.99 (dt, J = 3.1, 10.5 Hz, 1 H), 3.87-8.83 (m, 1 H), 3.79-3.77 (m, 1
H), 3.76-3.70 (m, 2 H), 3.49-3.44 (m, 2 H); 13C NMR (150 MHz, D2O): δ (ppm) 166.2,
154.8, 151.8, 141.6, 102.6, 94.1, 88.4, 88.3, 83.2, 73.8, 72.0, 69.6, 68.3, 67.4, 64.9, 60.2,
50.3, 50.2; HRMS-FAB: [M] calcd. for C18H25N3O17P2+ 617.0659 Found: 617.0656.
P'-[2-deoxy-2-[(2,2,2-trifluoroacetyl)amino]-α-D-glucopyranosyl] ester-uridine
5'-(trihydrogen diphosphate) (UDP-GlcN-TFA, 29)—White fluffy powder; 1H NMR
(600 MHz, D2O): δ (ppm) 7.88 (d, J = 8.11 Hz, 1H), 5.90 (m, 2H), 5.58-5.51 (dd, 1H, J =
7.0 Hz, 3.2 Hz), 4.29 (m, 2H), 4.21 (s, 1H), 4.20-4.14 (m, 1H), 4.11 (ddd, J = 11.68, 5.39,
3.12 Hz, 1H), 4.04 (d, J = 10.57 Hz, 1H), 3.88 (dd, J = 20.10, 9.82 Hz, 2H), 3.81 (d, J =
11.83 Hz, 1H), 3.78-3.73 (m, 1H), 3.52 (dd, J = 9.53, 5.39 Hz, 1H); 13C NMR (150 MHz,
D2O): δ (ppm) 166.4, 160.0, 151.9, 141.8, 117.0, 102.7, 93.9, 88.5, 83.2, 73.9, 73.1, 70.3,
69.7, 69.5, 64.9, 60.2, 54.4; HRMS-FAB: [M−H] calcd. for C17H23F3N3O17P2− 660.0460
Found: 660.0463.
P'-[2-deoxy-2-[(1-oxo-2-ethen-1-yl)amino]-2-deoxy-α-D-glucopyranosyl] ester-
uridine 5'-(trihydrogen diphosphate) (UDP-GlcN-ene, 30)—White fluffy
powder; 1H NMR (800 MHz, D2O): δ (ppm) 7.88 (d, J = 8.09 Hz, 1H), 6.35-6.29 (dd, J =
10.4, 18.4 Hz, 1H), 6.19-6.13(d, J = 16.8 Hz, 1H), 5.92-5.86 (m, 2H), 5.74-5.68 (d, J = 10.4
Hz, 1H), 5.46-5.42 (m, 1H), 4.31-4.25 (m, 2H), 4.21-4.18 (m, 1H), 4.18-4.08 (m, 2H),
3.97-3.93 (m, 1H), 3.88-3.84 (m, 1H), 3.78-3.73 (m, 3H), 3.50-3.46 (m, 1H); 13C NMR (200
MHz, D2O): δ (ppm) 168.7, 166.1, 151.7, 141.4, 129.6, 127.9, 102.5, 94.4, 88.3, 83.1, 73.7,
72.9, 70.9, 69.5, 69.3, 64.8, 60.1, 53.6; HRMS-FAB: [M−H] calcd. for
C18H26N3O17P2−618.0743 Found: 618.0741.
P'-[2-(acetylamino)-2-deoxy-α-D-galactopyranosyl] ester-uridine 5'-(trihydrogen
diphosphate), (UDP-GalNAc, 31)—1H NMR (500 MHz, D2O): δ (ppm) 7.79 (d, J = 8.2
Hz, 1 H), 5.81 (br d, J = 4.2 Hz, 1 H); 5.79 (br d, J = 8.3, 1 H); 5.39 (dd, J = 6.9, 3.3 Hz, 1
H); 4.22-4.19 (m, 2 H), 4.13-4.08 (m, 3 H), 4.05-4.01 (m, 2 H); 3.88 (d, J = 3.0 Hz, 1 H),
3.78 (dd, J = 11.8, 3.2 Hz, 1 H); 3.73 (m, 1 H), 3.62 (m, 1H), 1.92 (s, 3 H); HRMS-FAB:
[M] calcd. for C17H27N3O17P2+ 607.0816 Found: 607.0818.
P'-[2-(1-oxo-2-propyn-1-yl)amino-2-deoxy-α-D-galactopyranosyl] ester-uridine
5'-(trihydrogen diphosphate) (UDP-GalN-alkyne, 32)—White fluffy powder; 1H
NMR (600 MHz, D2O): δ (ppm) 7.87 (d, J = 8.1 Hz, 1 H), 5.89 (d, J = 4.8 Hz, 1 H), 5.86 (d,
J = 8.2 Hz, 1 H), 5.50 (dd, J = 3.4, 6.9 Hz, 1 H), 4.28 (m, 2 H), 4.22 (dt, J = 3.1, 10.6 Hz, 1
H), 4.20 (m, 1 H), 4.17 (m, 1 H), 4.11-4.09 (m, 2 H), 3.97 (br d, J = 3.0 Hz, 1 H), 3.91 (dd, J
= 3.1, 10.9 Hz, 1 H), 3.70-3.64 (m, 3 H); 13C NMR (150 MHz, D2O): δ (ppm) 166.2, 155.0,
151.8, 141.6, 102.6, 94.2, 88.4, 83.2, 83.1, 73.7, 72.0, 69.7, 68.3, 67.5, 65.0, 60.9, 50.3,
50.2; HRMS-FAB: [M] calcd. for C18H25N3O17P2+ 617.0659 Found: 617.0661.
P'-[2-azido-2-deoxy-α-D-glucopyranosyl] ester-uridine 5'-(trihydrogen
diphosphate) (UDP-GlcN3, 33)—UMP-morpholidate (211 mg, 0.303 mmol) was dried
by dissolving in anhydrous pyridine (5 mL) and concentrating in vacuo three times. Fully
deprotected phosphate 5 (77 mg, 0.217 mmol) was converted to its PyH+ form by passing
through an Amberlite (PyH+) column. UMP-Morpholidate was dissolved in pyridine (5 mL)
and added to phosphate 5 (PyH+). The reaction mixture was stirred for 5 days at room
temperature. The solvent was removed by concentration and the resulting residue was
dissolved in H2O (10 mL). Insoluble material was removed through filtration and the soluble
filtrate was concentrated in vacuo. The residue was loaded onto a BioGel P2 column (2.5 ×
65 cm) and eluted with H2O. Fractions were collected and those containing the product as
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determined by TLC (nBuOH/HCO2H/H2O = 4/8/1) were combined and freeze-dried to
afford a white powder (50 mg, 0.0756 mmol, 35%).
1H NMR (500 MHz, D2O): δ (ppm) 7.90 (d, J = 8.12 Hz, 1H), 5.91 (m, 2H), 5.61 (dd, J =
7.48, 3.32 Hz, 1H), 4.30 (m, 2H), 4.23-4.18 (m, 1H), 4.15 (m, 2H), 3.89-3.83 (m, 2H), 3.78
(dd, J = 12.47, 2.34 Hz, 1H), 3.71 (dd, J = 12.51, 4.28 Hz, 1H), 3.46 (dd, J = 10.12, 9.16 Hz,
1H), 3.30 (m, 1H); 13C NMR (125 MHz, D2O): δ (ppm) 166.6, 152.2, 141.9, 102.9, 94.6,
88.5, 83.5, 74.0, 73.0, 70.9, 69.9, 69.6, 63.1, 63.0, 60.3; HRMS-FAB: [M−H] calcd. for
C15H22N5O16P2− 590.0542 Found: 590.0539.
P'-[2-amino-2-deoxy-α-D-glucopyranosyl] ester-uridine 5'-(trihydrogen
diphosphate) (UDP-GlcNH2, 34)—1H NMR (800 MHz, D2O): δ (ppm) 7.87 (d, J = 8.09
Hz, 1H), 5.93-5.85 (m, 2H), 5.64-5.56 (m, 1H), 4.29 (d, J = 2.66 Hz, 2H), 4.23-4.19 (m,
1H), 4.19-4.09 (m, 2H), 3.85-3.81 (m, 1H), 3.80-3.72 (m, 2H), 3.72-3.66 (m, 1H), 3.45-3.39
(m, 1H), 3.01-2.91 (m, 1H); 13C NMR (200 MHz, D2O): δ (ppm) 166.6, 152.2, 141.9, 102.7,
94.7, 88.5, 83.1, 73.8, 73.2, 71.8, 69.6, 69.1, 65.0, 60.1, 54.7; HRMS-FAB: [M−H] calcd.
for C15H24N3O16P2− 564.0637 Found: 564.0638.
P'-[2-deoxy-2-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-
yl]-1-oxopentyl]amino]-α-D-glucopyranosyl] ester uridine 5'-(trihydrogen
diphosphate) (UDP-GlcN-biotin, 35)—To a stirred solution of 34 (5 mg, 8.2 µmol) in
HEPES buffer (2.5 mL, pH 8) was added 2.5 mL of a 10mM biotin-NHS solution in DMF at
0 °C. The reaction mixture was stirred for 2 h at 0 °C then concentrated. The crude mixture
was purified on a BioGel P2 column (2.5 × 65cm) and eluted with H2O. Fractions were
collected and those containing the product as determined by TLC (nBuOH/HCO2H/H2O =
4/8/1) were combined and freeze-dried to afford 35 as a white powder.
1H NMR (600 MHz, D2O): δ (ppm) 7.92-7.87 (d, J = 7.8 Hz, 1H), 5.92-5.83 (m, 2H),
5.44-5.39 (m, 1H), 4.54-4.49 (m, 1H), 4.37-4.33 (m, 1H), 4.31-4.24 (m, 2H), 4.21-4.18 (m,
1H), 4.18-4.08 (m, 2H), 3.95-3.90 (m, 1H), 3.88-3.83 (m, 1H), 3.82-3.77 (m, 1H), 3.76-3.69
(m, 2H), 3.49-3.43 (m, 1H), 2.95-2.88 (m, 1H), 2.72-2.65 (m, 1H), 2.32-2.25 (m, 1H),
1.70-1.29 (m, 8H); 13C NMR (150 MHz, D2O): δ 177.5, 166.2, 158.1, 153.3, 141.7, 102.6,
94.6, 84.5, 83.1, 73.8, 73.0, 70.9, 69.6, 64.9, 62.0, 60.2, 55.1, 48.1, 39.7, 35.4, 27.9, 27.5,
25.0; HRMS-FAB: [M−H] calcd. for C25H38N5O18P2S− 790.1413 Found: 790.1401.
P'-[2-deoxy-2-[[Fluorenylmethoxycarbonyl]amino]-α-D-glucopyranosyl] ester
uridine 5'-(trihydrogen diphosphate) (UDP-GlcN-Fmoc, 36)—To a stirred solution
of 34 (5 mg, 8.2 µmol) in 1,4-dioxane/H2O, 1/1 (0.8 mL) was added NaHCO3 (6.9 mg, 8.2
µmol) and FmocCl (5.3 mg, 20.5 µmol). The reaction was stirred overnight at room
temperature then concentrated. The crude mixture was purified on a BioGel P2 column (2.5
× 65 cm) and eluted with H2O. Fractions were collected and those containing the product as
determined by TLC (nBuOH/HCO2H/H2O, 4/8/1) were combined and freeze-dried to afford
36 as a white powder.
1H NMR (600 MHz, D2O): δ (ppm) 7.92-7.87 (d, J = 7.8 Hz, 1H), 5.92-5.83 (m, 2H),
5.44-5.39 (m, 1H), 4.54-4.49 (m, 1H), 4.37-4.33 (m, 1H), 4.31-4.24 (m, 2H), 4.21-4.18 (m,
1H), 4.18-4.08 (m, 2H), 3.95-3.90 (m, 1H), 3.88-3.83 (m, 1H), 3.82-3.77 (m, 1H), 3.76-3.69
(m, 2H), 3.49-3.43 (m, 1H), 2.95-2.88 (m, 1H), 2.72-2.65 (m, 1H), 2.32-2.25 (m, 1H),
1.70-1.29 (m, 8H); 13C NMR (150 MHz, D2O): δ (ppm) 163.1, 162.9, 143.5, 141.0, 140.8,
128.0, 127.5, 125.5, 125.4, 120.1, 117.3, 102.3, 94.9, 88.5, 82.8, 73.6, 73.0, 71.7, 71.2, 64.9,
60.4, 46.8; HRMS-FAB: [M−H] calcd. for C30H34N3O18P2− 786.1318 Found: 786.1318.
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ester uridine 5'-(trihydrogen diphosphate) (UDP-GlcN-tBoc, 37)—Boc2O (4.53
µL, 0.0197 mmol) was added to a stirred solution of 34 (8 mg, 0.0131 mmol) in 1,4-
dioxane/H2O, 1/1 (1 mL). The pH of the solution was adjusted to pH 10 using 10% NaOH
(aq.) and the reaction was stirred overnight at room temperature. A second portion of Boc2O
(4.53 µL, 0.0197 mmol) was added and the reaction was again stirred overnight at room
temperature. Ethyl acetate (1 mL) was added to the reaction mixture and the organic phase
was removed from the resulting biphasic mixture. The aqueous phase was loaded onto a
BioGel P2 column (2.5 × 65cm) and eluted with H2O. Fractions were collected and those
containing the product as determined by TLC (nBuOH/HCO2H/H2O = 4/8/1) were
combined and freeze-dried to afford 37 as a white powder (5.0 mg, 0.007 mmol, 30%).
1H NMR (500 MHz, D2O): δ (ppm) 7.96 (d, J = 8.00 Hz, 1H), 6.00 (d, J = 4.00 Hz, 1H),
5.98-5.95 (m, 2H), 5.54-5.49 (m, 1H), 4.37 (t, J = 4.33 Hz, 2H), 4.29 (s, 1H), 4.24 (s, 1H),
4.20 (dd, J = 6.04, 2.82 Hz, 1H), 3.93 (dd, J = 10.00, 3.16 Hz, 1H), 3.86-3.82 (m, 1H), 3.72
(d, J = 5.77 Hz, 1H), 3.68 (s, 1H), 3.54 (d, J = 9.43 Hz, 1H), 1.45 (s, 9H); 13C NMR (125
MHz, D2O): δ (ppm) 178.2, 167. 4, 157.9, 141.5, 102.7, 95.0, 88.0, 85.2, 81.3, 73.8, 72.9,
69.6, 69.5, 65.9, 64.8, 60.2, 55.0, 27.6; HRMS-FAB: [M−H] calcd. for C20H32N3O18P2−
664.1162 Found: 664.1166.
Radioactive assay
A given UDP-hexosamine analog (1–4 mM) and radioactive 3H-UDP-GlcUA (0.6–1 mM,
0.1 µCi) were co-incubated in 20–50 µL reactions containing 50 mM Tris pH 7.2, 1 mM
MnCl2, (as well as 1 M ethylene glycol for PmHAS and PmCS) with 0.5–45 µg of purified
recombinant enzyme at 30°C for 3–16 hrs. The reaction mixture was then quenched with
detergent and analyzed by descending paper chromatography.23 As a negative control for
assay background, a reaction with no UDP-hexosamine was tested in parallel (chain
polymerization can only occur when UDP-GlcUA and a functional UDP- hexosamine are
present simultaneously).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Chemical synthesis of UDP-GlcN derivatives
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Table 1
GlcNAc/GalNAc-1-phosphate analog acceptance by GlmU
Substrate R Yield (%) Product
GlcNAc & analogs 5 N3 n.r. -
6 NH2 n.r. -
7* 85 UDP-GlcNAc, 27
13 50 UDP-GlcN-alkyne, 28
22 78 UDP-GlcN-TFA, 29
26 65 UDP-GlcN-ene, 30
GalNAc & analogs 9* 70 UDP-GalNAc, 31
18 60 UDP-GalN-alkyne, 32
*
natural precursor
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Table 2
Analog usage by GAG synthases as monitored by co-polymerization assay.5, 23 The incorporation of
[3H]GlcUA radioactivity into polysaccharide is shown.
[3H]GlcUA incorporation (disintegrations/min × 10−3)
UDP-donor PmHAS PmCS PmHS1 PmHS2
27a 70–120 nab 25–80 25–70
28 1 na 12 16
29 34 na NSc 12
30 7 na 12 14
33 NSd na NSd NSd
35 NSd na NSd NSd
36 NS na NS 1.2
37 6 na 13 13
31a na 110d na na
32 na 82d na na
a




NS, not significant (≤5-fold over background of the negative control without any UDP-hexosamine present)
d
Values for overnight reaction time
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